Harpeth Capital Serves as Exclusive Financial Advisor to MediGO

Harpeth Capital is pleased to announce that it served as exclusive financial advisor to MediGO, Inc. in connection with the sale of the company to CareDx, Inc. (NASDAQ: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers.

Headquartered in Baltimore, MediGO is dedicated to combatting the challenges surrounding access to donated organs by digitally transforming donation and transplantation workflows to increase organ utilization and save more lives. Its comprehensive software platform optimizes complex logistics from referral to recovery and during the critical movement of organs and teams, giving organ procurement organizations (OPOs) and transplant centers the ability to unify decentralized stakeholders, coordinate resources, and make vital decisions with the goal of increasing organ utilization and improving equity and access to transplantation.

MediGO’s innovative healthcare supply chain technology and software solutions have been recognized by Edison Awards and Fast Company for their disruptive technology and are powered by proprietary algorithms and machine learning. At the end of 2022, MediGO became a recipient of the National Kidney Foundation Innovation Fund Investment.

“It was a pleasure to work with Scott Plank and the MediGO team on such an important endeavor,” said Chuck Byrge, CEO of Harpeth Capital. “As part of CareDx, MediGO will continue to make an impact by delivering lifesaving organs and enabling better outcomes.”

More details can be found here.